Drugmakers are looking for ways to deter counterfeiters, and so contract manufacturers are having to as well. Shanghai-based WuXi PharmaTech intends to provide a solution to its clients.
WuXi PharmaTech, China's largest pharma outsourcing outfit, is investing in a startup that makes tiny, edible bar codes designed to prevent drug counterfeiting, planning to offer the same technology to its manufacturing customers.
Fresh off scoring U.S. certification for its genomics lab, China's WuXi PharmaTech is amping up its lab testing services, buying into Illumina's $1,000 genome technology and teaming up with Pacific Biomarkers to broaden its assay menu.
WuXi PharmaTech boosted its revenue 15.6% last year, and China's largest CRO is expecting to match that growth in the new year, counting on steady demand for manufacturing and a larger share of the U.S. research market.
Pharma giant AstraZeneca has pulled the plug on a fleet of its in-development drugs but let live a rheumatoid arthritis treatment being co-developed with Chinese CRO giant WuXi PharmaTech.
WuXi PharmaTech, China's largest CRO, banked another strong revenue quarter thanks to escalating demand for clinical trials in its home country, and now the company is raising its annual profit expectations by about 7.6%.
WuXi PharmaTech says it has expanded a biologics plant in Shanghai by adding two 2,000-liter disposable bioreactors. The facility already has two cell culture suites containing the 500-liter and 1,000-liter disposable bioreactors in operation.
WuXi PharmaTech won CLIA certification for its Shanghai genomics lab, making it the first such outfit in China to meet U.S. testing standards.
WuXi PharmaTech, China's largest CRO, is counting on the burgeoning drug development market in its home country to deliver a big 2013, stretching its annual revenue guidance after another quarterly boost.
For CROs running trials around the globe, amassing loads of data is no sweat, but sharing it with sponsors in disparate countries and keeping it all in line for an eventual regulatory application can be daunting. With that in mind, WuXi PharmaTech, Inflamax Research and CROS NT have all signed deals for eClinical software to manage their trials.